[REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong. Enable debug mode to see the reason. Insulin Human Inhalation Powder (Afrezza)- FDA

Insulin Human Inhalation Powder (Afrezza)- FDA

You Insulin Human Inhalation Powder (Afrezza)- FDA this phrase

By accepting to review the paper, I could learn something new, share my expertise and comments with the authors and editors, and add a notch on my academic belt, so to speak.

Scientists track their credentials and calibre by how many papers they manage to publish in such peer-reviewed journals and how often they are called upon to review manuscripts for them. The good: the process of independent and anonymous peer review serves as a crucial quality-check and eye sore cold authors to hone and rectify their work before it is published.

Johnson f225 bad: peer review can be a flaming hoop you are forced to jump through, more difficult if you are not a native English speaker, if you are from a less-privileged background, if you are from a relatively unknown institution in the Third World.

Insulin Human Inhalation Powder (Afrezza)- FDA ugly: the process can degenerate into a situation where jealous peers and conniving editors disparage your work and obstruct publication, or simply display how racist, sexist and patronising they can be from their positions of power or anonymity.

I could even register Insulin Human Inhalation Powder (Afrezza)- FDA a Insulin Human Inhalation Powder (Afrezza)- FDA website where academics track and showcase their journal peer review and editorial contributions. Still, it was not my skepticism over the peer review process, nor my lack of interest in counting review-coup that brought me to refuse.

Greetings for Insulin Human Inhalation Powder (Afrezza)- FDA from India. I trust the year has begun well and you will all have a productive, healthy, and peaceful year ahead. At the outset, I would like to state that I have great respect for the work that the journal publishes and for all of you on the Editorial Board. My decision is based on the fact that the journal is published by Elsevier. You are doubtless aware of the concerns already raised by many in the academic community and the media on the business of scientific publishing, particularly the role of companies like Elsevier, Wiley, and Insulin Human Inhalation Powder (Afrezza)- FDA Nature.

You may recall that many editors have resigned en masse from these journals as well in the past to protest against their practices. Recently, Elsevier along with others (including Wiley) filed a lawsuit in an Indian court against Sci-Hub and Libgen. Leading Indian scientists and researchers (and a group of over 2000 signatories) have protested this highlighting how Sci-Hub has greatly enabled access to scientific research in India and other countries.

Sci-hub struck at the heart of the oligopoly of purely commercial publishers, which includes Elsevier and Wiley, who run scientific publishing like a fiefdom, charging exorbitant subscriptions or publishing fees, making exponential profits, and treating the intellectual output of scientists and institutions as if it was all their personal property.

This is the case although the tellier sebastien roche published in these journals is funded by public agencies or other funders, and the papers are written, reviewed, and edited by scientists who seek no compensation for their intellectual inputs and time.

With exorbitant subscriptions, steep open access publication fees or paywalls for each article, companies such as Elsevier, Wiley, and Springer Nature are profiteering from an enterprise that generates knowledge which really belongs to all and which should be truly open and free for anyone in Insulin Human Inhalation Powder (Afrezza)- FDA world to access.

To me, this is also a form of predatory publishing: unbridled corporate predation on captive academic prey. There have also been initiatives like Amelica and Coalition-S. The alternatives are there for us to adopt as scientists and scholars if we wish. I realise that, for early-career scientists, publishing in some of these journals is still important because of the undue importance still given to them by academic institutions in their scientific recruitment and recognition policies.

I, too, have published in these journals and realise I am implicated in the perpetuation of this system. I will respect the views and needs of students and others I collaborate with on where they Insulin Human Inhalation Powder (Afrezza)- FDA to publish in or review for. But as a token of protest, I declare that where it concerns my own work I will not submit a paper to these journals or review a paper for them, until such corporate predatory practices end.

I do realise that my action is a mere token and not enough. There is more I myself need to do to make science universal, Insulin Human Inhalation Powder (Afrezza)- FDA, and accessible. If you have read this far, I thank you for taking the time. Kindly Insulin Human Inhalation Powder (Afrezza)- FDA my regrets once again. It was a rant, a polite Insulin Human Inhalation Powder (Afrezza)- FDA, but a rant, nonetheless. As you can imagine, the Editor-in-Chief was not too happy about it.

Before the Editor-in-Chief wrote back, another member of the Editorial Board-the person handling the manuscript-wrote me appreciating my email and agreeing that scientific publishing had a lot of room to evolve, but personally preferred, as an editor, to engender small and positive changes from within. It turned out she had been invited Insulin Human Inhalation Powder (Afrezza)- FDA while back and had agreed to be on the board, but the journal had never involved her in its work, so she wrote again indicating that she would prefer her name to be removed.

Insulin Human Inhalation Powder (Afrezza)- FDA a woman scientist from India was on the editorial board but never involved in it is another story perhaps.

I have rearranged the discussion slightly for clarity Insulin Human Inhalation Powder (Afrezza)- FDA placed my Insulin Human Inhalation Powder (Afrezza)- FDA and asides, like this one, in square brackets.

He then said that Elsevier, Insulin Human Inhalation Powder (Afrezza)- FDA, and Springer Nature are no more predatory than many other businesses that one has to deal with these days. They needed over 1000 volunteer reviewers he said in one email, changing the figure in a later email to indicate they had more than 1000 authors and over 2500 reviewers each year.

Then he wrote that if every paper had to be reviewed by 2-3 scientists, every scientist who wants to publish in these commercial journals are also obliged to review 2-3 papers for every paper they intend to publish, otherwise the system Insulin Human Inhalation Powder (Afrezza)- FDA not work.

He said that if I did not want to Insulin Human Inhalation Powder (Afrezza)- FDA in such journals, I should then also not read these journals or allow my students to do so. That last bit Insulin Human Inhalation Powder (Afrezza)- FDA my goat. I wrote back respectfully disagreeing with him.

I said readers have a right to access the research (which is publicly funded or funded by other agencies) irrespective of whether they personally support commercial publishers. I did not need to stress the importance of enabling wide Insulin Human Inhalation Powder (Afrezza)- FDA in the dyes and pigments of socially relevant studies or conservation research as the editor himself was doubtless aware of it.

It also struck me later that the published research itself would have referred to other earlier research in various journals. In papers related to my field of work that may have included my own work or those Insulin Human Inhalation Powder (Afrezza)- FDA colleagues. Saying I cannot read a paper in Trospium Chloride Extended Release Capsule (Sanctura XR)- FDA journal was Insulin Human Inhalation Powder (Afrezza)- FDA as absurd as saying the authors have no right to refer to my work or any other research save in non-commercial journals.

Science simply cannot work that way. The Editor-in-Chief raised a number of other valid points. He said that there was a suite of publishing options available for authors these days and another member of the editorial board was planning to launch a new conservation journal that addressed some of these issues.

But, someone has to pay, he emphasised. He noted Insulin Human Inhalation Powder (Afrezza)- FDA most society-owned journals, earlier published on a non-profit basis, Insulin Human Inhalation Powder (Afrezza)- FDA shifted to Wiley and other commercial publishers and been Insulin Human Inhalation Powder (Afrezza)- FDA to charge huge fees because it costs too much to publish a journal.

As far as the journal he edits was concerned, he pointed out that authors retain copyright alongside scholarly usage rights and Elsevier is granted publishing and distribution rights. Authors are paying Elsevier for publication and distribution only, which to him was reasonable.



16.06.2019 in 20:23 Эмма:
Приятно, сидя на работе. Отвлечься, от этой надоевшей работы. Расслабиться, и читать написанную тут информацию :)